{"asctime": "2026-01-05 22:04:42", "levelname": "WARNING", "name": "root", "message": "Redis connection failed: Error 10061 connecting to localhost:6379. No connection could be made because the target machine actively refused it.. Using database fallback for account locking.", "timestamp": "2026-01-05T17:04:42.412294+00:00"}
{"asctime": "2026-01-05 22:04:42", "levelname": "INFO", "name": "root", "message": "Token blacklist initialized with database backend", "timestamp": "2026-01-05T17:04:42.434317+00:00"}
{"asctime": "2026-01-05 22:04:57", "levelname": "INFO", "name": "data_utils.vector_db", "message": "Successfully connected to Pinecone", "timestamp": "2026-01-05T17:04:57.918800+00:00"}
{"asctime": "2026-01-05 22:06:27", "levelname": "WARNING", "name": "passlib.handlers.bcrypt", "message": "(trapped) error reading bcrypt version", "exc_info": "Traceback (most recent call last):\n  File \"C:\\Users\\user\\Desktop\\metamed_backend\\.venv\\Lib\\site-packages\\passlib\\handlers\\bcrypt.py\", line 620, in _load_backend_mixin\n    version = _bcrypt.__about__.__version__\n              ^^^^^^^^^^^^^^^^^\nAttributeError: module 'bcrypt' has no attribute '__about__'", "timestamp": "2026-01-05T17:06:27.323408+00:00"}
{"asctime": "2026-01-05 22:06:34", "levelname": "INFO", "name": "root", "message": "Created refresh token for user test@gmail.com", "timestamp": "2026-01-05T17:06:34.123281+00:00"}
{"asctime": "2026-01-05 22:06:34", "levelname": "INFO", "name": "root", "message": "User logged in successfully", "email": "test@gmail.com", "role": "doctor", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:06:34.124143+00:00"}
{"asctime": "2026-01-05 22:06:35", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/auth/token", "method": "POST", "status_code": 200, "process_time": "14742.84ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:06:35.493701+00:00"}
{"asctime": "2026-01-05 22:06:35", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:56980 - \"POST /api/auth/token HTTP/1.1\" 200", "timestamp": "2026-01-05T17:06:35.495321+00:00"}
{"asctime": "2026-01-05 22:07:17", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:07:17.064938+00:00"}
{"asctime": "2026-01-05 22:07:21", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:07:21.575885+00:00"}
{"asctime": "2026-01-05 22:07:27", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:07:27.507648+00:00"}
{"asctime": "2026-01-05 22:07:28", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/paper-types", "method": "GET", "status_code": 200, "process_time": "13497.48ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:07:28.784209+00:00"}
{"asctime": "2026-01-05 22:07:28", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:55157 - \"GET /api/evidence/paper-types HTTP/1.1\" 200", "timestamp": "2026-01-05T17:07:28.785908+00:00"}
{"asctime": "2026-01-05 22:07:28", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/categories", "method": "GET", "status_code": 200, "process_time": "13521.07ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:07:28.790650+00:00"}
{"asctime": "2026-01-05 22:07:28", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:55156 - \"GET /api/evidence/categories HTTP/1.1\" 200", "timestamp": "2026-01-05T17:07:28.791699+00:00"}
{"asctime": "2026-01-05 22:07:30", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:07:30.375448+00:00"}
{"asctime": "2026-01-05 22:07:30", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/files", "method": "GET", "status_code": 200, "process_time": "15420.28ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:07:30.712258+00:00"}
{"asctime": "2026-01-05 22:07:30", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:55158 - \"GET /api/evidence/files?page=1&page_size=10 HTTP/1.1\" 200", "timestamp": "2026-01-05T17:07:30.713720+00:00"}
{"asctime": "2026-01-05 22:07:32", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:07:32.263292+00:00"}
{"asctime": "2026-01-05 22:07:35", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:07:35.598147+00:00"}
{"asctime": "2026-01-05 22:07:36", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/categories", "method": "GET", "status_code": 200, "process_time": "7846.80ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:07:36.643703+00:00"}
{"asctime": "2026-01-05 22:07:36", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:54779 - \"GET /api/evidence/categories HTTP/1.1\" 200", "timestamp": "2026-01-05T17:07:36.645596+00:00"}
{"asctime": "2026-01-05 22:07:38", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:07:38.364320+00:00"}
{"asctime": "2026-01-05 22:07:38", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/files", "method": "GET", "status_code": 200, "process_time": "9978.05ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:07:38.775336+00:00"}
{"asctime": "2026-01-05 22:07:38", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:54777 - \"GET /api/evidence/files?page=1&page_size=10 HTTP/1.1\" 200", "timestamp": "2026-01-05T17:07:38.776362+00:00"}
{"asctime": "2026-01-05 22:07:38", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/files", "method": "GET", "status_code": 200, "process_time": "9980.84ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:07:38.777366+00:00"}
{"asctime": "2026-01-05 22:07:38", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:54778 - \"GET /api/evidence/files?page=1&page_size=10 HTTP/1.1\" 200", "timestamp": "2026-01-05T17:07:38.778200+00:00"}
{"asctime": "2026-01-05 22:07:40", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:07:40.617023+00:00"}
{"asctime": "2026-01-05 22:07:42", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/paper-types", "method": "GET", "status_code": 200, "process_time": "11876.73ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:07:42.581318+00:00"}
{"asctime": "2026-01-05 22:07:42", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:55156 - \"GET /api/evidence/paper-types HTTP/1.1\" 200", "timestamp": "2026-01-05T17:07:42.582357+00:00"}
{"asctime": "2026-01-05 22:07:42", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/files", "method": "GET", "status_code": 200, "process_time": "12200.24ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:07:42.905683+00:00"}
{"asctime": "2026-01-05 22:07:42", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:55157 - \"GET /api/evidence/files?page=1&page_size=10 HTTP/1.1\" 200", "timestamp": "2026-01-05T17:07:42.906924+00:00"}
{"asctime": "2026-01-05 22:07:59", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:07:59.971408+00:00"}
{"asctime": "2026-01-05 22:08:00", "levelname": "INFO", "name": "utils.doctor_response", "message": "Starting doctor_response with question: what are heart failure condition...", "timestamp": "2026-01-05T17:08:00.006531+00:00"}
{"asctime": "2026-01-05 22:08:00", "levelname": "INFO", "name": "utils.doctor_response", "message": "Calling query_doc...", "timestamp": "2026-01-05T17:08:00.007444+00:00"}
{"asctime": "2026-01-05 22:08:00", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Starting query_doc with query: what are heart failure condition...", "timestamp": "2026-01-05T17:08:00.010531+00:00"}
{"asctime": "2026-01-05 22:08:00", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Attempting similarity search...", "timestamp": "2026-01-05T17:08:00.011307+00:00"}
{"asctime": "2026-01-05 22:11:58", "levelname": "INFO", "name": "httpx", "message": "HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"", "timestamp": "2026-01-05T17:11:58.821166+00:00"}
{"asctime": "2026-01-05 22:12:03", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Retrieved 8 documents from vector DB", "timestamp": "2026-01-05T17:12:03.241639+00:00"}
{"asctime": "2026-01-05 22:12:03", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Starting reranking...", "timestamp": "2026-01-05T17:12:03.242899+00:00"}
{"asctime": "2026-01-05 22:12:07", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Reranking completed, got 3 reranked docs", "timestamp": "2026-01-05T17:12:07.440660+00:00"}
{"asctime": "2026-01-05 22:12:07", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "query_doc completed successfully", "timestamp": "2026-01-05T17:12:07.441784+00:00"}
{"asctime": "2026-01-05 22:12:07", "levelname": "INFO", "name": "utils.doctor_response", "message": "query_doc returned: type=<class 'dict'>, value={'reranked_docs': [{'id': 'doc_3', 'index': 3, 'score': 0.068787284, 'document': {'id': 'doc_3', 'text': 'torantagonismeitherbySB204741orbyT erguridedecreased RVhypertrophyandimprovedRVcontractilefunctionwhen g i v e nt oa n i m a l sw i t he s t a b l i s h e dR Vf a i l u r e .O u rd a t a proposes that 5 HT2BR antagonists and, more specifically, Terguride, which is clinically approved and well tolerated, might serve as a new cardioprotective tool for the treatment ofRVF. BioMedResearchInternational 7 Conflict of Interests Allotherauthorsdeclarenocompetingconflictofinterests. Acknowledgments The authors received funding from Universities of Giessen and Marburg Lung Centre (UGMLC). Dr. Ghofrani andDr. Schermuly report personal fees from Ergonex, Gilead,Novartis, and Pfizer. Dr. Ghofrani, Dr. Schermuly, and Dr.Weissmann received research funding from Ergonex andPfizer. References [ 1 ]N .F .V o e l k e l ,R .A .Q u a i f e ,L .A .L e i n w a n de ta l . ,‚Äú R i g h t ventricular function and failure: report of a National Heart, Lung,andBloodInstituteworkinggrouponcellularandmolec ular mechanisms of right heart failure,‚Äù Circulation ,v o l .1 1 4 , no .17 ,pp .1883‚Äì1891,2006. [2] H.J.Bogaard,K.Abe,A.V .Noordegmaf,andN.F .V oelkel,‚ÄúThe right ventricle under pressure: cellular and molecular mecha nismsofright heartfailureinpulmonaryhypertension,‚Äù Chest, vol.135,no.3,pp.794‚Äì804,2009. [3] M. Guglin and S. Verma, ‚ÄúRight side of heart failure,‚Äù Heart FailureReviews ,vol.17 ,no .3,pp .511 ‚Äì527 ,2012. [4] D. A. Mann and F. Oakley, ‚ÄúSerotonin paracrine signaling in tissue fibrosis,‚Äù Biochimica et Biophysica Acta: Molecular Basis ofDisease ,vol.1832,no .7 ,pp .905‚Äì910,2013. [5] K. G. Shyu, ‚ÄúSerotonin 5 HT2B receptor in cardiac fibroblast contributestocardiachypertrophy:anewtherapeutictargetfor heartfailure?‚Äù CirculationResearch ,vol.104,pp .1 ‚Äì3,2009 . [ 6 ]O .L a i r e z ,T .C o g n e t ,S .S c h a a ke ta l . ,‚Äú R o l eo fs e r o t o n i n5 HT2A receptors in the development of cardiac hypertrophy inresponsetoaorticconstrictioninmice,‚Äù JournalofNeuralTrans mission,vol.120,no .6,pp .927 ‚Äì935,2013. [ 7 ]C .G .N e b i g i l ,D . S .C h o i ,A .D i e r i c he ta l . ,‚Äú S e r o t o n i n2 B receptor is required for heart development,‚Äù Proceedings of the National Academy of Sciences of the United States of America , vol. 97, no. 17, pp. 9508‚Äì9513, 2000. [8] C. G. Nebigil, P. Hickel, N. Messaddeq et al., ‚ÄúAblation of serotonin5 HT2Breceptorsinmiceleadstoabnormalcardiac structure and function,‚Äù Circulation ,v o l .1 0 3 ,n o .2 4 ,p p .2 9 7 3 ‚Äì 2979,2001. [9] F. Jaffr ¬¥e, J. Callebert, A. Sarre et al., ‚ÄúInvolvement of the sero tonin 5 HT2B receptor in cardiac hypertrophy linked to sym pathetic stimulation: control of interleukin 6, interleukin 1 ùõΩ, andtumornecrosisfactor ùõºcytokineproductionbyventricular fibroblasts,‚Äù Circulation ,vol.110,no .8,pp .969‚Äì97 4,2004. [10] L. Monassier, M. A. Laplante, F. Jaffr ¬¥e, P. Bousquet, L. Maroteaux, and J. de Champlain, ‚ÄúSerotonin 5 HT2B receptorblockade prevents reactive oxygen species induced cardiac hypertrophy in mice,‚Äù Hypertension ,v o l .5 2 ,n o .2 ,p p .30 1 ‚Äì 30 7 , 2008. [11] F.Jaffr ¬¥e,P.Bonnin,J.Callebertetal.,‚ÄúSerotoninandangiotensin receptors in cardiac fibroblasts coregulate adrenergic dependentcardiachypertrophy,‚Äù Circulation Research ,vol.104, no .1,pp .113‚Äì123,2009 .[12] L.Abenhaim,Y.Moride,F.Brenotetal.,‚ÄúAppetite suppressant drugs and the risk of primary pulmonary hypertension. Inter national Primary Pulmonary Hypertension Study Group,‚Äù The NewEnglandJournalofMedicine ,vol.335,pp .609‚Äì619 ,1996. [13]'}}, {'id': 'doc_5', 'index': 5, 'score': 0.041773878, 'document': {'id': 'doc_5', 'text': 'overloadedrightheart.Thebiochemicalandcel lularresponsestocardiachypertrophyandfailureareyettobefullyexplored[ 3].Elucidatingthefunctionalandhistologicaleffects of pharmaceutical interventions on the development ofcardiachypertrophyandfailurecanhelpustounderstand the underlying cellular mechanisms. Previous reports sug gestedthataninterplayofTGF ùõΩ3and5 HTsignalingmight exist,astheblockadeofthe5HT2breceptorresultedincom pletecessationofTGFùõΩ3inducedmechanicalstrengthening, suggesting TGFùõΩ/ 5 H Ts i g n a l i n ga sap o t e n tm e c h a n i s m for control of biomechanical remodeling of atrioventricular cushions during development [ 34]. Thus it is tempting to speculate that the effect of serotonin on 5 HT signaling ismediatedbyTGF beta.Thus,theantagonismofthe5 HT2BRmight even be more promising as a strategy for therapeutic intervention in RVF, since the 5 HT2B signaling is not restricted to the heart but has also been implicated in thedevelopmentofpulmonaryarterialhypertension(PAH)[ 14]. Inhibition of excessive receptor activation in the lung andin the heart in PAH provides a strong rationale for clinicalevaluationofsuchagentsinthetreatmentofPAHandRVF. A key role for 5 HT2BR activation in left ventricular remodeling processes and the development and progressionof heart failure has been suggested by [ 9,10]. The 5 HT2BR expression in cardiac fibroblasts and their contribution todevelopment of cardiac hypertrophy were shown in 2009[5,11]. Interestingly, Lairez et al. demonstrated in 2013 that, aftertransverseaorticconstriction,leftventricular5 HT2ARexpression was transiently increased and selective blockadeofthereceptorpreventedthedevelopmentofcardiachyper trophy[6]. Terguride is known as a high affinity modulator of neu rotransmitter receptors including serotonin, dopamine, andùõº2 adrenergicreceptors[ 35‚Äì37].Herewehavestudieditasa prototypic drug for the therapeutic intervention by 5 HT2Rblockade in RVF. This study demonstrates that TergurideandSB204741(a)improvehemodynamics,(b)restorecardiacoutput, and (c) prevent and reverse cardiac fibrosis inducedby PAB operation in mice. Given our findings, blocking of the 5 HT2B receptor by specific antagonists may be a useful therapy for patients suffering from right heart disease andwarrantsforfutureclinicalinvestigations. 5. Conclusion In this study, we investigated whether a therapeutic inter vention using 5 HT2B receptor antagonists Terguride and SB204741 exerts antifibrotic potency in chronic experimen tal pressure overload induced RVF in mice. As serotonin receptor antagonism in experimental RVF has not been addressedbyotherresearchgroupsyet,wedemonstratethat administration of both Terguride and SB204741 weakens myocardial structural changes by reducing RV hypertrophy andfibrosisinPABmice.Inconclusion,serotonin2Brecep torantagonismeitherbySB204741orbyT erguridedecreased RVhypertrophyandimprovedRVcontractilefunctionwhen g i v e nt oa n i m a l sw i t he s t a b l i s h e dR Vf a i l u r e .O u rd a t a proposes that 5 HT2BR antagonists and, more specifically, Terguride, which is clinically approved and well tolerated, might serve as a new cardioprotective tool for the treatment ofRVF. BioMedResearchInternational 7 Conflict of Interests Allotherauthorsdeclarenocompetingconflictofinterests. Acknowledgments The authors received funding from Universities of Giessen and Marburg Lung Centre (UGMLC). Dr. Ghofrani andDr. Schermuly report personal fees from Ergonex, Gilead,Novartis, and Pfizer. Dr.'}}, {'id': 'doc_2', 'index': 2, 'score': 0.032283258, 'document': {'id': 'doc_2', 'text': 'ResearchArticle 5 HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure Wiebke Janssen,1,2Yves Schymura,3Tatyana Novoyatleva,1,2 Baktybek Kojonazarov,1,2Mario Boehm,1,2Astrid Wietelmann,3Himal Luitel,1,2 Kirsten Murmann,1,2Damian Richard Krompiec,1,2Aleksandra Tretyn,3 Soni Savai Pullamsetti,3Norbert Weissmann,1,2Werner Seeger,1,2,3 Hossein Ardeschir Ghofrani,1,2and Ralph Theo Schermuly1,2 1UniversitiesofGiessenandMarburgLungCentre(UGMLC),Aulweg130,35392Giessen,Germany 2GermanCenterforLungResearch(DZL),35392Giessen,Germany 3Max Planck InstituteforHeartandLungResearch,Ludwigstrasse43,61231BadNauheim,Germany CorrespondenceshouldbeaddressedtoRalphTheoScher muly;ralph.schermuly@innere.med.uni giessen.de Received22August2014;Accepted28October2014 AcademicEditor:ShiroMizuno Copyright ¬© 2015 WiebkeJanssenetal.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense, whichpermitsunrestricteduse,distribution,andreproductio ninanymedium,providedtheoriginalworkisproperlycited. Objective. The serotonin (5 HT) pathway was shown to play a role in pulmonary hypertension (PH), but its functions in right ventricularfailure(RVF)remainpoorlyunderstood.TheaimofthecurrentstudywastoinvestigatetheeffectsofTerguride(5 HT2A and2Breceptorantagonist)orSB204741(5 HT2Breceptorantagonist)onrightheartfunctionandstructureuponpulmonaryarterybanding(PAB)inmice. Methods.SevendaysafterPAB,miceweretreatedfor14dayswithTerguride(0.2mg/kgbid)orSB204741 (5mg/kg day). Right heart function and remodeling were assessed by right heart catheterization, magnetic resonance imaging (MRI), and histomorphometric methods. Total secreted collagen content was determined in mouse cardiac fibroblasts isolatedfrom RV tissues. Results. Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heartfunctioninmiceafterPAB.Moreover,5 HT2BreceptorantagonistsdiminishedTGF beta1inducedcollagensynthesisofRV cardiacfibroblasts invitro.Conclusion .5 HT2Breceptorantagonistsreducecollagendeposition,therebyinhibitingrightventricular fibrosis.Chronictreatmentpreventedthedevelopmentandprogressionofpressureoverload inducedRVFinmice.Thus,5 HT2B receptorantagonistsrepresentavaluablenoveltherapeuticapproachforRVF. 1. Introduction Sustained pressure overload of the right ventricle (RV) is a significant pathophysiological factor in several cardiovas cular disorders, including pulmonary hypertension (PH). Outstandingly, RV failure (RVF) is the most common cause of death in patients with severe PH and is increasinglyrecognizedasanimportantclinicalproblem[ 1,2]. Long term increase in pressure consequently results in RV hypertrophy (RVH). Initial cardiac hypertrophy can be consideredasabeneficialresponsetochangedhemodynamic parameters.Duringdiseaseprogressionthemaladaptivecar diac hypertrophy slowly proceeds to a decompensated state.WiththeprogressionofPH,theRVdilates,becomesfibrotic,andfinallyundergoesfunctionalfailure,theultimatecauseof deathinPH[ 3]. An accumulating body of evidence clearly underlines a significant role of 5 hydroxytryptamine (serotonin, 5 HT)in development and progression of LV hypertrophy (LVH)and fibrosis [ 4‚Äì6]. It was shown that serotonin, via the 5 HT2B receptor (5 HT2BR), regulates cardiac developmentand function [ 7,8]. Also it was demonstratedthat 5 HT2BR is essential for isoproterenol induced cardiac hypertrophy,whichisregulatedbyinterleukin 6(IL 6),interleukin 1 ùõΩ(IL'}}], 'file_names': ['5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart fail..._1.pdf', '5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart fail..._1.pdf', '5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart fail..._1.pdf']}", "timestamp": "2026-01-05T17:12:07.447996+00:00"}
{"asctime": "2026-01-05 22:12:07", "levelname": "INFO", "name": "utils.doctor_response", "message": "Extracted 3 reranked docs and 3 file names", "timestamp": "2026-01-05T17:12:07.455795+00:00"}
{"asctime": "2026-01-05 22:12:07", "levelname": "INFO", "name": "utils.doctor_response", "message": "Context formatted, length: 10751", "timestamp": "2026-01-05T17:12:07.457177+00:00"}
{"asctime": "2026-01-05 22:12:07", "levelname": "INFO", "name": "utils.doctor_response", "message": "Full message prepared, length: 10804", "timestamp": "2026-01-05T17:12:07.458526+00:00"}
{"asctime": "2026-01-05 22:12:07", "levelname": "INFO", "name": "utils.doctor_response", "message": "Creating OpenAI stream...", "timestamp": "2026-01-05T17:12:07.459285+00:00"}
{"asctime": "2026-01-05 22:12:13", "levelname": "INFO", "name": "httpx", "message": "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"", "timestamp": "2026-01-05T17:12:13.308306+00:00"}
{"asctime": "2026-01-05 22:12:13", "levelname": "INFO", "name": "utils.doctor_response", "message": "OpenAI stream created successfully", "timestamp": "2026-01-05T17:12:13.316413+00:00"}
{"asctime": "2026-01-05 22:12:16", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:12:16.538361+00:00"}
{"asctime": "2026-01-05 22:12:18", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:12:18.444298+00:00"}
{"asctime": "2026-01-05 22:12:20", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:12:20.287032+00:00"}
{"asctime": "2026-01-05 22:12:25", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:12:25.509974+00:00"}
{"asctime": "2026-01-05 22:12:26", "levelname": "INFO", "name": "utils.doctor_response", "message": "Starting to stream response...", "timestamp": "2026-01-05T17:12:26.551690+00:00"}
{"asctime": "2026-01-05 22:12:26", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/chat/doctor/stream", "method": "POST", "status_code": 200, "process_time": "268334.47ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:12:26.589514+00:00"}
{"asctime": "2026-01-05 22:12:26", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:57757 - \"POST /api/chat/doctor/stream HTTP/1.1\" 200", "timestamp": "2026-01-05T17:12:26.590386+00:00"}
{"asctime": "2026-01-05 22:12:28", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:12:28.376181+00:00"}
{"asctime": "2026-01-05 22:12:31", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:12:31.061943+00:00"}
{"asctime": "2026-01-05 22:12:32", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/categories", "method": "GET", "status_code": 200, "process_time": "18729.92ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:12:32.103880+00:00"}
{"asctime": "2026-01-05 22:12:32", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:62941 - \"GET /api/evidence/categories HTTP/1.1\" 200", "timestamp": "2026-01-05T17:12:32.106139+00:00"}
{"asctime": "2026-01-05 22:12:32", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/paper-types", "method": "GET", "status_code": 200, "process_time": "18738.51ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:12:32.113194+00:00"}
{"asctime": "2026-01-05 22:12:32", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:62942 - \"GET /api/evidence/paper-types HTTP/1.1\" 200", "timestamp": "2026-01-05T17:12:32.117556+00:00"}
{"asctime": "2026-01-05 22:12:32", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/categories", "method": "GET", "status_code": 200, "process_time": "18748.19ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:12:32.122617+00:00"}
{"asctime": "2026-01-05 22:12:32", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:58617 - \"GET /api/evidence/categories HTTP/1.1\" 200", "timestamp": "2026-01-05T17:12:32.124938+00:00"}
{"asctime": "2026-01-05 22:12:34", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:12:34.319230+00:00"}
{"asctime": "2026-01-05 22:12:34", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/files", "method": "GET", "status_code": 200, "process_time": "21257.49ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:12:34.631502+00:00"}
{"asctime": "2026-01-05 22:12:34", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:62943 - \"GET /api/evidence/files?page=1&page_size=10 HTTP/1.1\" 200", "timestamp": "2026-01-05T17:12:34.632775+00:00"}
{"asctime": "2026-01-05 22:12:34", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/files", "method": "GET", "status_code": 200, "process_time": "21250.61ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:12:34.636135+00:00"}
{"asctime": "2026-01-05 22:12:34", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:58615 - \"GET /api/evidence/files?page=1&page_size=10 HTTP/1.1\" 200", "timestamp": "2026-01-05T17:12:34.638438+00:00"}
{"asctime": "2026-01-05 22:12:34", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/files", "method": "GET", "status_code": 200, "process_time": "21268.33ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:12:34.641362+00:00"}
{"asctime": "2026-01-05 22:12:34", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:58616 - \"GET /api/evidence/files?page=1&page_size=10 HTTP/1.1\" 200", "timestamp": "2026-01-05T17:12:34.649819+00:00"}
{"asctime": "2026-01-05 22:12:36", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:12:36.517017+00:00"}
{"asctime": "2026-01-05 22:12:41", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/paper-types", "method": "GET", "status_code": 200, "process_time": "8738.30ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:12:41.084674+00:00"}
{"asctime": "2026-01-05 22:12:41", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:49411 - \"GET /api/evidence/paper-types HTTP/1.1\" 200", "timestamp": "2026-01-05T17:12:41.086329+00:00"}
{"asctime": "2026-01-05 22:12:41", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/evidence/files", "method": "GET", "status_code": 200, "process_time": "7266.08ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:12:41.896378+00:00"}
{"asctime": "2026-01-05 22:12:41", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:62941 - \"GET /api/evidence/files?page=1&page_size=10 HTTP/1.1\" 200", "timestamp": "2026-01-05T17:12:41.897791+00:00"}
{"asctime": "2026-01-05 22:13:06", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:13:06.025201+00:00"}
{"asctime": "2026-01-05 22:13:06", "levelname": "INFO", "name": "utils.doctor_response", "message": "Starting doctor_response with question: WHAT ARE THE CASUSES OF HEART FAILURE...", "timestamp": "2026-01-05T17:13:06.037466+00:00"}
{"asctime": "2026-01-05 22:13:06", "levelname": "INFO", "name": "utils.doctor_response", "message": "Calling query_doc...", "timestamp": "2026-01-05T17:13:06.038121+00:00"}
{"asctime": "2026-01-05 22:13:06", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Starting query_doc with query: WHAT ARE THE CASUSES OF HEART FAILURE...", "timestamp": "2026-01-05T17:13:06.038746+00:00"}
{"asctime": "2026-01-05 22:13:06", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Attempting similarity search...", "timestamp": "2026-01-05T17:13:06.039304+00:00"}
{"asctime": "2026-01-05 22:13:08", "levelname": "INFO", "name": "httpx", "message": "HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"", "timestamp": "2026-01-05T17:13:08.423331+00:00"}
{"asctime": "2026-01-05 22:13:11", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Retrieved 8 documents from vector DB", "timestamp": "2026-01-05T17:13:11.943954+00:00"}
{"asctime": "2026-01-05 22:13:11", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Starting reranking...", "timestamp": "2026-01-05T17:13:11.945291+00:00"}
{"asctime": "2026-01-05 22:13:16", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Reranking completed, got 3 reranked docs", "timestamp": "2026-01-05T17:13:16.524656+00:00"}
{"asctime": "2026-01-05 22:13:16", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "query_doc completed successfully", "timestamp": "2026-01-05T17:13:16.527675+00:00"}
{"asctime": "2026-01-05 22:13:16", "levelname": "INFO", "name": "utils.doctor_response", "message": "query_doc returned: type=<class 'dict'>, value={'reranked_docs': [{'id': 'doc_7', 'index': 7, 'score': 0.17258982, 'document': {'id': 'doc_7', 'text': 'torantagonismeitherbySB204741orbyT erguridedecreased RVhypertrophyandimprovedRVcontractilefunctionwhen g i v e nt oa n i m a l sw i t he s t a b l i s h e dR Vf a i l u r e .O u rd a t a proposes that 5 HT2BR antagonists and, more specifically, Terguride, which is clinically approved and well tolerated, might serve as a new cardioprotective tool for the treatment ofRVF. BioMedResearchInternational 7 Conflict of Interests Allotherauthorsdeclarenocompetingconflictofinterests. Acknowledgments The authors received funding from Universities of Giessen and Marburg Lung Centre (UGMLC). Dr. Ghofrani andDr. Schermuly report personal fees from Ergonex, Gilead,Novartis, and Pfizer. Dr. Ghofrani, Dr. Schermuly, and Dr.Weissmann received research funding from Ergonex andPfizer. References [ 1 ]N .F .V o e l k e l ,R .A .Q u a i f e ,L .A .L e i n w a n de ta l . ,‚Äú R i g h t ventricular function and failure: report of a National Heart, Lung,andBloodInstituteworkinggrouponcellularandmolec ular mechanisms of right heart failure,‚Äù Circulation ,v o l .1 1 4 , no .17 ,pp .1883‚Äì1891,2006. [2] H.J.Bogaard,K.Abe,A.V .Noordegmaf,andN.F .V oelkel,‚ÄúThe right ventricle under pressure: cellular and molecular mecha nismsofright heartfailureinpulmonaryhypertension,‚Äù Chest, vol.135,no.3,pp.794‚Äì804,2009. [3] M. Guglin and S. Verma, ‚ÄúRight side of heart failure,‚Äù Heart FailureReviews ,vol.17 ,no .3,pp .511 ‚Äì527 ,2012. [4] D. A. Mann and F. Oakley, ‚ÄúSerotonin paracrine signaling in tissue fibrosis,‚Äù Biochimica et Biophysica Acta: Molecular Basis ofDisease ,vol.1832,no .7 ,pp .905‚Äì910,2013. [5] K. G. Shyu, ‚ÄúSerotonin 5 HT2B receptor in cardiac fibroblast contributestocardiachypertrophy:anewtherapeutictargetfor heartfailure?‚Äù CirculationResearch ,vol.104,pp .1 ‚Äì3,2009 . [ 6 ]O .L a i r e z ,T .C o g n e t ,S .S c h a a ke ta l . ,‚Äú R o l eo fs e r o t o n i n5 HT2A receptors in the development of cardiac hypertrophy inresponsetoaorticconstrictioninmice,‚Äù JournalofNeuralTrans mission,vol.120,no .6,pp .927 ‚Äì935,2013. [ 7 ]C .G .N e b i g i l ,D . S .C h o i ,A .D i e r i c he ta l . ,‚Äú S e r o t o n i n2 B receptor is required for heart development,‚Äù Proceedings of the National Academy of Sciences of the United States of America , vol. 97, no. 17, pp. 9508‚Äì9513, 2000. [8] C. G. Nebigil, P. Hickel, N. Messaddeq et al., ‚ÄúAblation of serotonin5 HT2Breceptorsinmiceleadstoabnormalcardiac structure and function,‚Äù Circulation ,v o l .1 0 3 ,n o .2 4 ,p p .2 9 7 3 ‚Äì 2979,2001. [9] F. Jaffr ¬¥e, J. Callebert, A. Sarre et al., ‚ÄúInvolvement of the sero tonin 5 HT2B receptor in cardiac hypertrophy linked to sym pathetic stimulation: control of interleukin 6, interleukin 1 ùõΩ, andtumornecrosisfactor ùõºcytokineproductionbyventricular fibroblasts,‚Äù Circulation ,vol.110,no .8,pp .969‚Äì97 4,2004. [10] L. Monassier, M. A. Laplante, F. Jaffr ¬¥e, P. Bousquet, L. Maroteaux, and J. de Champlain, ‚ÄúSerotonin 5 HT2B receptorblockade prevents reactive oxygen species induced cardiac hypertrophy in mice,‚Äù Hypertension ,v o l .5 2 ,n o .2 ,p p .30 1 ‚Äì 30 7 , 2008. [11] F.Jaffr ¬¥e,P.Bonnin,J.Callebertetal.,‚ÄúSerotoninandangiotensin receptors in cardiac fibroblasts coregulate adrenergic dependentcardiachypertrophy,‚Äù Circulation Research ,vol.104, no .1,pp .113‚Äì123,2009 .[12] L.Abenhaim,Y.Moride,F.Brenotetal.,‚ÄúAppetite suppressant drugs and the risk of primary pulmonary hypertension. Inter national Primary Pulmonary Hypertension Study Group,‚Äù The NewEnglandJournalofMedicine ,vol.335,pp .609‚Äì619 ,1996. [13]'}}, {'id': 'doc_1', 'index': 1, 'score': 0.13061774, 'document': {'id': 'doc_1', 'text': 'parameters.Duringdiseaseprogressionthemaladaptivecar diac hypertrophy slowly proceeds to a decompensated state.WiththeprogressionofPH,theRVdilates,becomesfibrotic,andfinallyundergoesfunctionalfailure,theultimatecauseof deathinPH[ 3]. An accumulating body of evidence clearly underlines a significant role of 5 hydroxytryptamine (serotonin, 5 HT)in development and progression of LV hypertrophy (LVH)and fibrosis [ 4‚Äì6]. It was shown that serotonin, via the 5 HT2B receptor (5 HT2BR), regulates cardiac developmentand function [ 7,8]. Also it was demonstratedthat 5 HT2BR is essential for isoproterenol induced cardiac hypertrophy,whichisregulatedbyinterleukin 6(IL 6),interleukin 1 ùõΩ(IL 1ùõΩ),andtumornecrosisfactorùõº(TNFùõº)cytokineproduction b yc a r d i a cfi b r o b l a s t s[ 9]. Moreover, 5 HT2BR blockade has a l s ob e e ns h o w nt op r e v e n tc a r d i a ch y p e r t r o p h yi n d u c e dby angiotensin II or isoproterenol infusion [ 10]. In 2009,Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 438403, 8 pages http://dx.doi.org/10.1155/2015/438403 2 BioMedResearchInternational Jaffr¬¥ee ta l .f o u n dt h a tt h ee x p r e s s i o no f5 H T 2 B Rb yn o n cardiomyocytesisrequiredforisoproterenol inducedcardiachypertrophyandthat5 HT2BRisoverexpressedinheartsofpatientswithcongestiveheartfailure[ 11].Inadditiontothat, several research groups revealed a role for serotonin in thepathogenesis of PAH [ 12‚Äì16]. Regarding different forms of chronic LV failure (LVF) extensive experimental knowledge was achieved over the past decades. Although the conceptsofmechanismsofRVFhavebeenlargelyformedonthebasisof the analysis of LVF models, thus the molecular processescontributing to the maintenance and disease of the RV arepoorly investigated. We therefore investigated the effects oftheselective5 HT2BRantagonist(SB204741)andacombined5 HT2AR and 5 HT2BR antagonist (Terguride) on RVHand fibrosis in a preclinical animal model of RV pressureoverload.First,weexaminedtheexpressionofthe5 HT2ARand 5 HT2BR in the mouse model of RV pressure overload,induced by pulmonary artery banding (PAB). Importantly,only 5 HT2BR expression was elevated after PAB. Our datashow that the 5 HT2BR antagonist SB204741 and antago nist of both 5 HT2A and 2B receptors Terguride preventRV myocardial hypertrophy. Furthermore, both antagonistsexerted antifibrotic effects after long term use in chronicexperimentalpressureoverload inducedRVFinmice.Anal yses of RV cardiac fibroblasts treated with 5 HT2BR antag onists substantiated the role of the 5 HT2BR in collagenproduction. 2. Methods 2.1. Animals. Adult male C57BL/6J mice (body weight 20‚Äì23g) were purchased from Charles River Laboratories(Sulzfeld,Germany).Animalswerehousedundercontrolledconditionswithfreeaccesstorodentchowandtapwater.All invivoprocedureswereapprovedbytheAnimalEthicsCom mittee of the Regierungspr ¬®asidium Darmstadt (Az. B2/229) in accordance with institutionalguidelines that comply withnationalandinternationalregulations. 2.2. Animal Experimental Design. The effects of 5 HT sig naling pathway blockade by 5 HT2B receptor (5 HT2BR)antagonists were investigated in mice after banding of themain pulmonary artery (PAB). For the experiment, micewere randomly assigned for placebo or chronic Tergurideor SB204741 therapy: (1) sham operated animals, (2) micesubjected to PAB with no active treatment, designated asp l a c e b og r o u p ,( 3 )m i c es u b j e c t e dt oP A Bw i t hT e r g u r i d'}}, {'id': 'doc_3', 'index': 3, 'score': 0.10875559, 'document': {'id': 'doc_3', 'text': 'ResearchArticle 5 HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure Wiebke Janssen,1,2Yves Schymura,3Tatyana Novoyatleva,1,2 Baktybek Kojonazarov,1,2Mario Boehm,1,2Astrid Wietelmann,3Himal Luitel,1,2 Kirsten Murmann,1,2Damian Richard Krompiec,1,2Aleksandra Tretyn,3 Soni Savai Pullamsetti,3Norbert Weissmann,1,2Werner Seeger,1,2,3 Hossein Ardeschir Ghofrani,1,2and Ralph Theo Schermuly1,2 1UniversitiesofGiessenandMarburgLungCentre(UGMLC),Aulweg130,35392Giessen,Germany 2GermanCenterforLungResearch(DZL),35392Giessen,Germany 3Max Planck InstituteforHeartandLungResearch,Ludwigstrasse43,61231BadNauheim,Germany CorrespondenceshouldbeaddressedtoRalphTheoScher muly;ralph.schermuly@innere.med.uni giessen.de Received22August2014;Accepted28October2014 AcademicEditor:ShiroMizuno Copyright ¬© 2015 WiebkeJanssenetal.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense, whichpermitsunrestricteduse,distribution,andreproductio ninanymedium,providedtheoriginalworkisproperlycited. Objective. The serotonin (5 HT) pathway was shown to play a role in pulmonary hypertension (PH), but its functions in right ventricularfailure(RVF)remainpoorlyunderstood.TheaimofthecurrentstudywastoinvestigatetheeffectsofTerguride(5 HT2A and2Breceptorantagonist)orSB204741(5 HT2Breceptorantagonist)onrightheartfunctionandstructureuponpulmonaryarterybanding(PAB)inmice. Methods.SevendaysafterPAB,miceweretreatedfor14dayswithTerguride(0.2mg/kgbid)orSB204741 (5mg/kg day). Right heart function and remodeling were assessed by right heart catheterization, magnetic resonance imaging (MRI), and histomorphometric methods. Total secreted collagen content was determined in mouse cardiac fibroblasts isolatedfrom RV tissues. Results. Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heartfunctioninmiceafterPAB.Moreover,5 HT2BreceptorantagonistsdiminishedTGF beta1inducedcollagensynthesisofRV cardiacfibroblasts invitro.Conclusion .5 HT2Breceptorantagonistsreducecollagendeposition,therebyinhibitingrightventricular fibrosis.Chronictreatmentpreventedthedevelopmentandprogressionofpressureoverload inducedRVFinmice.Thus,5 HT2B receptorantagonistsrepresentavaluablenoveltherapeuticapproachforRVF. 1. Introduction Sustained pressure overload of the right ventricle (RV) is a significant pathophysiological factor in several cardiovas cular disorders, including pulmonary hypertension (PH). Outstandingly, RV failure (RVF) is the most common cause of death in patients with severe PH and is increasinglyrecognizedasanimportantclinicalproblem[ 1,2]. Long term increase in pressure consequently results in RV hypertrophy (RVH). Initial cardiac hypertrophy can be consideredasabeneficialresponsetochangedhemodynamic parameters.Duringdiseaseprogressionthemaladaptivecar diac hypertrophy slowly proceeds to a decompensated state.WiththeprogressionofPH,theRVdilates,becomesfibrotic,andfinallyundergoesfunctionalfailure,theultimatecauseof deathinPH[ 3]. An accumulating body of evidence clearly underlines a significant role of 5 hydroxytryptamine (serotonin, 5 HT)in development and progression of LV hypertrophy (LVH)and fibrosis [ 4‚Äì6]. It was shown that serotonin, via the 5 HT2B receptor (5 HT2BR), regulates cardiac developmentand function [ 7,8]. Also it was demonstratedthat 5 HT2BR is essential for isoproterenol induced cardiac hypertrophy,whichisregulatedbyinterleukin 6(IL 6),interleukin 1 ùõΩ(IL'}}], 'file_names': ['5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart fail..._1.pdf', '5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart fail..._1.pdf', '5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart fail..._1.pdf']}", "timestamp": "2026-01-05T17:13:16.543752+00:00"}
{"asctime": "2026-01-05 22:13:16", "levelname": "INFO", "name": "utils.doctor_response", "message": "Extracted 3 reranked docs and 3 file names", "timestamp": "2026-01-05T17:13:16.551129+00:00"}
{"asctime": "2026-01-05 22:13:16", "levelname": "INFO", "name": "utils.doctor_response", "message": "Context formatted, length: 10749", "timestamp": "2026-01-05T17:13:16.553392+00:00"}
{"asctime": "2026-01-05 22:13:16", "levelname": "INFO", "name": "utils.doctor_response", "message": "Full message prepared, length: 10807", "timestamp": "2026-01-05T17:13:16.557042+00:00"}
{"asctime": "2026-01-05 22:13:16", "levelname": "INFO", "name": "utils.doctor_response", "message": "Creating OpenAI stream...", "timestamp": "2026-01-05T17:13:16.558297+00:00"}
{"asctime": "2026-01-05 22:13:18", "levelname": "INFO", "name": "httpx", "message": "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"", "timestamp": "2026-01-05T17:13:18.761815+00:00"}
{"asctime": "2026-01-05 22:13:18", "levelname": "INFO", "name": "utils.doctor_response", "message": "OpenAI stream created successfully", "timestamp": "2026-01-05T17:13:18.763463+00:00"}
{"asctime": "2026-01-05 22:13:19", "levelname": "INFO", "name": "utils.doctor_response", "message": "Starting to stream response...", "timestamp": "2026-01-05T17:13:19.069083+00:00"}
{"asctime": "2026-01-05 22:13:19", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/chat/doctor/stream", "method": "POST", "status_code": 200, "process_time": "15334.26ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:13:19.072428+00:00"}
{"asctime": "2026-01-05 22:13:19", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:54058 - \"POST /api/chat/doctor/stream HTTP/1.1\" 200", "timestamp": "2026-01-05T17:13:19.073459+00:00"}
{"asctime": "2026-01-05 22:13:40", "levelname": "INFO", "name": "utils.doctor_response", "message": "Streaming completed", "timestamp": "2026-01-05T17:13:40.883800+00:00"}
{"asctime": "2026-01-05 22:19:47", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T17:19:47.246145+00:00"}
{"asctime": "2026-01-05 22:19:47", "levelname": "INFO", "name": "utils.doctor_response", "message": "Starting doctor_response with question: renel artery...", "timestamp": "2026-01-05T17:19:47.336246+00:00"}
{"asctime": "2026-01-05 22:19:47", "levelname": "INFO", "name": "utils.doctor_response", "message": "Calling query_doc...", "timestamp": "2026-01-05T17:19:47.337433+00:00"}
{"asctime": "2026-01-05 22:19:47", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Starting query_doc with query: renel artery...", "timestamp": "2026-01-05T17:19:47.339696+00:00"}
{"asctime": "2026-01-05 22:19:47", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Attempting similarity search...", "timestamp": "2026-01-05T17:19:47.341087+00:00"}
{"asctime": "2026-01-05 22:19:49", "levelname": "INFO", "name": "httpx", "message": "HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"", "timestamp": "2026-01-05T17:19:49.798973+00:00"}
{"asctime": "2026-01-05 22:19:53", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Retrieved 8 documents from vector DB", "timestamp": "2026-01-05T17:19:53.012697+00:00"}
{"asctime": "2026-01-05 22:19:53", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Starting reranking...", "timestamp": "2026-01-05T17:19:53.013800+00:00"}
{"asctime": "2026-01-05 22:19:56", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Reranking completed, got 3 reranked docs", "timestamp": "2026-01-05T17:19:56.405809+00:00"}
{"asctime": "2026-01-05 22:19:56", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "query_doc completed successfully", "timestamp": "2026-01-05T17:19:56.407086+00:00"}
{"asctime": "2026-01-05 22:19:56", "levelname": "INFO", "name": "utils.doctor_response", "message": "query_doc returned: type=<class 'dict'>, value={'reranked_docs': [{'id': 'doc_1', 'index': 1, 'score': 0.93306583, 'document': {'id': 'doc_1', 'text': 'vascular disease usually is greater to 40%. Several non invasive methods for diagnosis have been used in hypertensivepatients with a suspicion of renal arteries stenosis, such as colorDoppler ultrasound. The incorporation of echo enhancers (EE) tothe echographic technique has had a signiÔ¨Åcant impact for the yieldof the study. Objective: To analyze the feasibility of total visualization of main renal artery with and without EE. To determine the sensitivityand diagnostic speciÔ¨Åcity of the conventional color Doppler pa rameters for the diagnosis of RVH: renal peak systolic velocity(RePSV), renal aortic ratio (RAR): RePSV/peak systolic velocityat the abdominal aorta (AoPSV), with and without EE. A new in dex of velocities was also proposed: the renal hiliar index (ReHi Index): RePSV/renal hilum peak systolic velocity (ReHiPSV), andwas compared with conventional parameters in terms of sen sitivity and speciÔ¨Åcity, using angiography as the gold standardmethod. Materials and Methods: 77 patients were included (45 males, 32 females, mean age 54 years) between July 1998 and April2003. Echo Doppler analysis was made with and without EE,comparing the feasibility of visualization of the renal arteries in all their passage: proximal, medium, and distal. Three differ ent echo machines were used: Ving Med CFM 800 (2,5 MHzand 3,5 MHz transducer), Toshiba SSH 140 A (2,5 MHz and3,75 MHz transducer) and Hewlett Packard Image Point HX(2,5 MHz and 4,0 MHz transducer). An EE composed of 999mg of galactose and 1 mgof palmitic acid by each gram ofgrains was used with 300 mg/mL concentration. The direct pa rameters measured in the main renal artery were the following:(1) RePSV: as the highest Doppler velocity measured in sys tole in the main renal artery. (2) RAR: as the rate between re nal peak systolic velocity, RePSV, divided by aortic peak sys tolic velocity, AoPSV, measured at the abdominal aorta. (3) ReHiIndex: the rate between RePSV and renal hilum peak systolic ve locity, ReHiPSV, measured at the hilum in its extrarenal section.Stenosis was considered signiÔ¨Åcant when RePSV >200 cm/s, RAR>3.5 and new renal hiliar Index >2.7. Renal angiography was performed in 16 patients with echographic diagnosis of re nal artery stenosis. Statistical analyses included speciÔ¨Åcity, sensi bility, and relative risk calculations on the three mentioned directparameters. The Mantel Haenszel chisquare test was applied toanalyze statistically signiÔ¨Åcant differences between the discreteparameters. Results: 77 patients were examined with conventional color echo Doppler technique with and without EE. All 151 of 151 therenal arteries segments, proximal, medium and distal, were ob served with EE, (100% feasibility) and 137 of 151 without EE (91%feasibility) (p <0.001). Renal angiography revealed severe steno sis in 16 arteries ( >60%), 3 with moderate obstruction (40‚Äì59%), 10 normal, 2 occluded, and one absent.The diagnostic accuracyof the direct parameters for the diagnosis of severe renal steno sis was as follows: (1) RePSV >200 cm/s; 94% sensibility, 77% speciÔ¨Åcity, RR 9.17 (p <0.001). (2) RAR >3.5: 69% sensibility, 100% speciÔ¨Åcity, RR 3.6 (p <0.001). (3) New ReHi Index >2.7: 94% sensibility, 92% speciÔ¨Åcity, RR 12.24 (p <0.001). The values of urea and creatinine in blood before and after the intravenousadministration of EE were similar (p <0.72), showing EE as a well tolerated product. Conclusions: (1) The visualization feasibility of renal arteries im proved signiÔ¨Åcantly with'}}, {'id': 'doc_2', 'index': 2, 'score': 0.42321965, 'document': {'id': 'doc_2', 'text': 'ABSTRACTSABSTRACTS 1 DIFFERENT CLINICAL FEATURES OF AORTIC INTRAMU RAL HEMATOMA VERSUS DISSECTION INVOLVING THE DE SCENDING THORACIC AORTA F . Mariano, O. Pablo, C. Vicente, D. Alberto, B. Daniel, P . Rodolfo. Instituto del Corazon, Hospital Italiano de Buenos Aires, Argentina. Background: Although indicators of surgical and medical treat ment have been applied to patients with typical dissection (AD) ofthe descending thoracic aorta, the natural history of descendingaortic intramural hematoma (AIH) is not yet clearly known. Objective: The goal of this study was to test the hypothesis that the absence of Ô¨Çow communication through the intimal tear inAIH involving the descending aorta has a different clinical coursecompared with AD. Methods: We prospectively evaluated clinical and echocardio graphic data between AD (76 patients) and AIH (27 patients) ofthe descending thoracic aorta. Results: Patients had no differences In age, gender, or clinical presentation. The development of pleural effussion or periaortichematoma was more frequent in patients with AIH than it was inpatients with AD. AIH and AD had same predictors of complica tions at follow up: aortic diameter ( >5 cm) at diagnosis and per sistent back pain. Although medical treatment was selected in thesame proportion between groups, surgical treatment was more fre quently selected in AD (39% vs. 22%, p <0.01). AD patients who received surgical treatment had higher mortality than those withAIH (36% vs. 17%, p <0.01). There was no difference in mortality between patients who received medical treatment (15% in AD vs14% in AIH, p =0.7). In follow up imaging studies of 23 patients with AIH,6 patients (25%) showed complete resolution and 6 pa tients (25%) increased the descending aortic diameter. Typical ADdeveloped in 3 patients (13%). A three year survival rate did notshow signiÔ¨Åcant difference (82 ¬±6% in AIH vs 75 ¬±7% in AD, p=0.37). Conclusion: AIH of the descending thoracic aorta have rela tively frequent complications at follow up including dissection andaneurysm formation. Medical treatment with very close imagingfollow up and timed elective surgery in cases with complicationsallow better management for patients with AIH of the descendingthoracic aorta. 2 ULTRASOUND DOPPLER TECHNIQUE AND THE RENAL AR TERIES: DIAGNOSTIC IMPACT OF THE ECHO ENHANCER SHU 508A AND A NEW RENAL HILIAR VELOCITIES INDEX S. Chain, R.N. Herrera, G. Mercau, J. Klyver, S. Alonso, L. Abdo, J. Ochoa, J. Muntaner, R. Ronderos, E. Escudero. Magister deUltrasonido en Cardiologia, Universidad Nacional de La Plata, LaPlata, Argentina. Introduction: Renal vascular hypertension (RVH) accounts for 1‚Äì5% of the total population of patients with high blood pressure.In addition, the prevalence between patients with coronary and pe ripheral vascular disease usually is greater to 40%. Several non invasive methods for diagnosis have been used in hypertensivepatients with a suspicion of renal arteries stenosis, such as colorDoppler ultrasound. The incorporation of echo enhancers (EE) tothe echographic technique has had a signiÔ¨Åcant impact for the yieldof the study. Objective: To analyze the feasibility of total visualization of main renal artery with and without EE. To determine the sensitivityand diagnostic speciÔ¨Åcity of the conventional color Doppler pa rameters for the diagnosis of RVH: renal peak systolic velocity(RePSV), renal aortic ratio (RAR): RePSV/peak systolic velocityat the abdominal aorta (AoPSV), with and without'}}, {'id': 'doc_0', 'index': 0, 'score': 0.092359796, 'document': {'id': 'doc_0', 'text': \"severe steno sis in 16 arteries ( >60%), 3 with moderate obstruction (40‚Äì59%), 10 normal, 2 occluded, and one absent.The diagnostic accuracyof the direct parameters for the diagnosis of severe renal steno sis was as follows: (1) RePSV >200 cm/s; 94% sensibility, 77% speciÔ¨Åcity, RR 9.17 (p <0.001). (2) RAR >3.5: 69% sensibility, 100% speciÔ¨Åcity, RR 3.6 (p <0.001). (3) New ReHi Index >2.7: 94% sensibility, 92% speciÔ¨Åcity, RR 12.24 (p <0.001). The values of urea and creatinine in blood before and after the intravenousadministration of EE were similar (p <0.72), showing EE as a well tolerated product. Conclusions: (1) The visualization feasibility of renal arteries im proved signiÔ¨Åcantly with the EE use, increasing from 91% to 100%(p<0.001). (2) A new renal hiliar index (ReHi Index) was intro duced, with improved sensitivity and very acceptable speciÔ¨Åcity inrelation to conventional direct parameters like RePSV >200 cm/s and RAR >3.5 (p <0.0001). (3) EE showed an excellent security proÔ¨Åle in terms of renal tolerance, also allowing its use in patientswith deterioration of the renal function. 3 CARDIAC FUNCTION BY STRAIN IMAGING: KEY TO THE IN CREASED PERFORMANCE CAPACITIES OF ENDURANCE TRAINED ATHLETES P . Claessens, C. Claessens, M. Claessens, M. Claessens, J. Claessens. Eeuwfeestkliniek Antwerp Belgium. Background: To increase the performance capacity of a triath lete (Tri), a variety of adaptations are necessary. The heart is thecentral and the most important limiting factor. The structural heartadaptations in Tri have important repercussion on cardiac function.The left ventricular diastole shows speciÔ¨Åc characteristics that de termine performance capacity. Methods: 40 male Tri were compared with 31 active male con trols and with 112 patients with ischemic heart disease. All subjectsunderwent tissue Doppler and strain imaging. Results: The late diastolic Ô¨Ålling period in Tri has speciÔ¨Åc char acteristics. Tissue imaging demonstrated in Tri speciÔ¨Åc character istics of both the late passive diastolic Ô¨Ålling period and the earlyactive diastolic relaxation period. The signiÔ¨Åcant differences be tween the three groups concerning the strain values at the basaland the mid septum in the longitudinal axis by aortic valve closureand by mitral valve opening were extremely striking. The valuesof the end diastolic strain by the end of the a wave: negative inTri, near zero in normal controls, and marked positive in coronarypatients were fascinating (Ô¨Åg. 1). 204 ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech. Vol. 21, No. 2, 2004 Copyright of Echocardiography is the property of Wiley Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.\"}}], 'file_names': ['test.pdf', 'test.pdf', 'test.pdf']}", "timestamp": "2026-01-05T17:19:56.414266+00:00"}
{"asctime": "2026-01-05 22:19:56", "levelname": "INFO", "name": "utils.doctor_response", "message": "Extracted 3 reranked docs and 3 file names", "timestamp": "2026-01-05T17:19:56.417592+00:00"}
{"asctime": "2026-01-05 22:19:56", "levelname": "INFO", "name": "utils.doctor_response", "message": "Context formatted, length: 9911", "timestamp": "2026-01-05T17:19:56.418495+00:00"}
{"asctime": "2026-01-05 22:19:56", "levelname": "INFO", "name": "utils.doctor_response", "message": "Full message prepared, length: 9944", "timestamp": "2026-01-05T17:19:56.419198+00:00"}
{"asctime": "2026-01-05 22:19:56", "levelname": "INFO", "name": "utils.doctor_response", "message": "Creating OpenAI stream...", "timestamp": "2026-01-05T17:19:56.420037+00:00"}
{"asctime": "2026-01-05 22:19:58", "levelname": "INFO", "name": "httpx", "message": "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"", "timestamp": "2026-01-05T17:19:58.446701+00:00"}
{"asctime": "2026-01-05 22:19:58", "levelname": "INFO", "name": "utils.doctor_response", "message": "OpenAI stream created successfully", "timestamp": "2026-01-05T17:19:58.448109+00:00"}
{"asctime": "2026-01-05 22:19:58", "levelname": "INFO", "name": "utils.doctor_response", "message": "Starting to stream response...", "timestamp": "2026-01-05T17:19:58.688780+00:00"}
{"asctime": "2026-01-05 22:19:59", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/chat/doctor/stream", "method": "POST", "status_code": 200, "process_time": "14174.19ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T17:19:59.000554+00:00"}
{"asctime": "2026-01-05 22:19:59", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:56439 - \"POST /api/chat/doctor/stream HTTP/1.1\" 200", "timestamp": "2026-01-05T17:19:59.001626+00:00"}
{"asctime": "2026-01-05 22:20:25", "levelname": "INFO", "name": "utils.doctor_response", "message": "Streaming completed", "timestamp": "2026-01-05T17:20:25.949018+00:00"}
{"asctime": "2026-01-05 23:17:33", "levelname": "ERROR", "name": "root", "message": "Error checking account lock in database for test@gmail.com: (psycopg2.OperationalError) could not translate host name \"medicaldatabasecredentials-do-user-24924231-0.j.db.ondigitalocean.com\" to address: Name or service not known\n\n(Background on this error at: https://sqlalche.me/e/20/e3q8)", "timestamp": "2026-01-05T18:17:33.207828+00:00"}
{"asctime": "2026-01-05 23:18:26", "levelname": "INFO", "name": "root", "message": "Created refresh token for user test@gmail.com", "timestamp": "2026-01-05T18:18:26.626211+00:00"}
{"asctime": "2026-01-05 23:18:26", "levelname": "INFO", "name": "root", "message": "User logged in successfully", "email": "test@gmail.com", "role": "doctor", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T18:18:26.630909+00:00"}
{"asctime": "2026-01-05 23:18:28", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/auth/token", "method": "POST", "status_code": 200, "process_time": "67582.35ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T18:18:28.869851+00:00"}
{"asctime": "2026-01-05 23:18:28", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:58455 - \"POST /api/auth/token HTTP/1.1\" 200", "timestamp": "2026-01-05T18:18:28.871636+00:00"}
{"asctime": "2026-01-05 23:19:06", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T18:19:06.284293+00:00"}
{"asctime": "2026-01-05 23:19:06", "levelname": "INFO", "name": "utils.doctor_response", "message": "Starting doctor_response with question: renel artery...", "timestamp": "2026-01-05T18:19:06.302643+00:00"}
{"asctime": "2026-01-05 23:19:06", "levelname": "INFO", "name": "utils.doctor_response", "message": "Calling query_doc...", "timestamp": "2026-01-05T18:19:06.304176+00:00"}
{"asctime": "2026-01-05 23:19:06", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Starting query_doc with query: renel artery...", "timestamp": "2026-01-05T18:19:06.305418+00:00"}
{"asctime": "2026-01-05 23:19:06", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Attempting similarity search...", "timestamp": "2026-01-05T18:19:06.306134+00:00"}
{"asctime": "2026-01-05 23:19:11", "levelname": "INFO", "name": "httpx", "message": "HTTP Request: POST https://api.openai.com/v1/embeddings \"HTTP/1.1 200 OK\"", "timestamp": "2026-01-05T18:19:11.327582+00:00"}
{"asctime": "2026-01-05 23:19:28", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Retrieved 8 documents from vector DB", "timestamp": "2026-01-05T18:19:28.803673+00:00"}
{"asctime": "2026-01-05 23:19:28", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Starting reranking...", "timestamp": "2026-01-05T18:19:28.805480+00:00"}
{"asctime": "2026-01-05 23:19:49", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "Reranking completed, got 3 reranked docs", "timestamp": "2026-01-05T18:19:49.632149+00:00"}
{"asctime": "2026-01-05 23:19:49", "levelname": "INFO", "name": "Rag_Service.retrieval", "message": "query_doc completed successfully", "timestamp": "2026-01-05T18:19:49.633380+00:00"}
{"asctime": "2026-01-05 23:19:49", "levelname": "INFO", "name": "utils.doctor_response", "message": "query_doc returned: type=<class 'dict'>, value={'reranked_docs': [{'id': 'doc_1', 'index': 1, 'score': 0.93306583, 'document': {'id': 'doc_1', 'text': 'vascular disease usually is greater to 40%. Several non invasive methods for diagnosis have been used in hypertensivepatients with a suspicion of renal arteries stenosis, such as colorDoppler ultrasound. The incorporation of echo enhancers (EE) tothe echographic technique has had a signiÔ¨Åcant impact for the yieldof the study. Objective: To analyze the feasibility of total visualization of main renal artery with and without EE. To determine the sensitivityand diagnostic speciÔ¨Åcity of the conventional color Doppler pa rameters for the diagnosis of RVH: renal peak systolic velocity(RePSV), renal aortic ratio (RAR): RePSV/peak systolic velocityat the abdominal aorta (AoPSV), with and without EE. A new in dex of velocities was also proposed: the renal hiliar index (ReHi Index): RePSV/renal hilum peak systolic velocity (ReHiPSV), andwas compared with conventional parameters in terms of sen sitivity and speciÔ¨Åcity, using angiography as the gold standardmethod. Materials and Methods: 77 patients were included (45 males, 32 females, mean age 54 years) between July 1998 and April2003. Echo Doppler analysis was made with and without EE,comparing the feasibility of visualization of the renal arteries in all their passage: proximal, medium, and distal. Three differ ent echo machines were used: Ving Med CFM 800 (2,5 MHzand 3,5 MHz transducer), Toshiba SSH 140 A (2,5 MHz and3,75 MHz transducer) and Hewlett Packard Image Point HX(2,5 MHz and 4,0 MHz transducer). An EE composed of 999mg of galactose and 1 mgof palmitic acid by each gram ofgrains was used with 300 mg/mL concentration. The direct pa rameters measured in the main renal artery were the following:(1) RePSV: as the highest Doppler velocity measured in sys tole in the main renal artery. (2) RAR: as the rate between re nal peak systolic velocity, RePSV, divided by aortic peak sys tolic velocity, AoPSV, measured at the abdominal aorta. (3) ReHiIndex: the rate between RePSV and renal hilum peak systolic ve locity, ReHiPSV, measured at the hilum in its extrarenal section.Stenosis was considered signiÔ¨Åcant when RePSV >200 cm/s, RAR>3.5 and new renal hiliar Index >2.7. Renal angiography was performed in 16 patients with echographic diagnosis of re nal artery stenosis. Statistical analyses included speciÔ¨Åcity, sensi bility, and relative risk calculations on the three mentioned directparameters. The Mantel Haenszel chisquare test was applied toanalyze statistically signiÔ¨Åcant differences between the discreteparameters. Results: 77 patients were examined with conventional color echo Doppler technique with and without EE. All 151 of 151 therenal arteries segments, proximal, medium and distal, were ob served with EE, (100% feasibility) and 137 of 151 without EE (91%feasibility) (p <0.001). Renal angiography revealed severe steno sis in 16 arteries ( >60%), 3 with moderate obstruction (40‚Äì59%), 10 normal, 2 occluded, and one absent.The diagnostic accuracyof the direct parameters for the diagnosis of severe renal steno sis was as follows: (1) RePSV >200 cm/s; 94% sensibility, 77% speciÔ¨Åcity, RR 9.17 (p <0.001). (2) RAR >3.5: 69% sensibility, 100% speciÔ¨Åcity, RR 3.6 (p <0.001). (3) New ReHi Index >2.7: 94% sensibility, 92% speciÔ¨Åcity, RR 12.24 (p <0.001). The values of urea and creatinine in blood before and after the intravenousadministration of EE were similar (p <0.72), showing EE as a well tolerated product. Conclusions: (1) The visualization feasibility of renal arteries im proved signiÔ¨Åcantly with'}}, {'id': 'doc_2', 'index': 2, 'score': 0.42321965, 'document': {'id': 'doc_2', 'text': 'ABSTRACTSABSTRACTS 1 DIFFERENT CLINICAL FEATURES OF AORTIC INTRAMU RAL HEMATOMA VERSUS DISSECTION INVOLVING THE DE SCENDING THORACIC AORTA F . Mariano, O. Pablo, C. Vicente, D. Alberto, B. Daniel, P . Rodolfo. Instituto del Corazon, Hospital Italiano de Buenos Aires, Argentina. Background: Although indicators of surgical and medical treat ment have been applied to patients with typical dissection (AD) ofthe descending thoracic aorta, the natural history of descendingaortic intramural hematoma (AIH) is not yet clearly known. Objective: The goal of this study was to test the hypothesis that the absence of Ô¨Çow communication through the intimal tear inAIH involving the descending aorta has a different clinical coursecompared with AD. Methods: We prospectively evaluated clinical and echocardio graphic data between AD (76 patients) and AIH (27 patients) ofthe descending thoracic aorta. Results: Patients had no differences In age, gender, or clinical presentation. The development of pleural effussion or periaortichematoma was more frequent in patients with AIH than it was inpatients with AD. AIH and AD had same predictors of complica tions at follow up: aortic diameter ( >5 cm) at diagnosis and per sistent back pain. Although medical treatment was selected in thesame proportion between groups, surgical treatment was more fre quently selected in AD (39% vs. 22%, p <0.01). AD patients who received surgical treatment had higher mortality than those withAIH (36% vs. 17%, p <0.01). There was no difference in mortality between patients who received medical treatment (15% in AD vs14% in AIH, p =0.7). In follow up imaging studies of 23 patients with AIH,6 patients (25%) showed complete resolution and 6 pa tients (25%) increased the descending aortic diameter. Typical ADdeveloped in 3 patients (13%). A three year survival rate did notshow signiÔ¨Åcant difference (82 ¬±6% in AIH vs 75 ¬±7% in AD, p=0.37). Conclusion: AIH of the descending thoracic aorta have rela tively frequent complications at follow up including dissection andaneurysm formation. Medical treatment with very close imagingfollow up and timed elective surgery in cases with complicationsallow better management for patients with AIH of the descendingthoracic aorta. 2 ULTRASOUND DOPPLER TECHNIQUE AND THE RENAL AR TERIES: DIAGNOSTIC IMPACT OF THE ECHO ENHANCER SHU 508A AND A NEW RENAL HILIAR VELOCITIES INDEX S. Chain, R.N. Herrera, G. Mercau, J. Klyver, S. Alonso, L. Abdo, J. Ochoa, J. Muntaner, R. Ronderos, E. Escudero. Magister deUltrasonido en Cardiologia, Universidad Nacional de La Plata, LaPlata, Argentina. Introduction: Renal vascular hypertension (RVH) accounts for 1‚Äì5% of the total population of patients with high blood pressure.In addition, the prevalence between patients with coronary and pe ripheral vascular disease usually is greater to 40%. Several non invasive methods for diagnosis have been used in hypertensivepatients with a suspicion of renal arteries stenosis, such as colorDoppler ultrasound. The incorporation of echo enhancers (EE) tothe echographic technique has had a signiÔ¨Åcant impact for the yieldof the study. Objective: To analyze the feasibility of total visualization of main renal artery with and without EE. To determine the sensitivityand diagnostic speciÔ¨Åcity of the conventional color Doppler pa rameters for the diagnosis of RVH: renal peak systolic velocity(RePSV), renal aortic ratio (RAR): RePSV/peak systolic velocityat the abdominal aorta (AoPSV), with and without'}}, {'id': 'doc_0', 'index': 0, 'score': 0.092359796, 'document': {'id': 'doc_0', 'text': \"severe steno sis in 16 arteries ( >60%), 3 with moderate obstruction (40‚Äì59%), 10 normal, 2 occluded, and one absent.The diagnostic accuracyof the direct parameters for the diagnosis of severe renal steno sis was as follows: (1) RePSV >200 cm/s; 94% sensibility, 77% speciÔ¨Åcity, RR 9.17 (p <0.001). (2) RAR >3.5: 69% sensibility, 100% speciÔ¨Åcity, RR 3.6 (p <0.001). (3) New ReHi Index >2.7: 94% sensibility, 92% speciÔ¨Åcity, RR 12.24 (p <0.001). The values of urea and creatinine in blood before and after the intravenousadministration of EE were similar (p <0.72), showing EE as a well tolerated product. Conclusions: (1) The visualization feasibility of renal arteries im proved signiÔ¨Åcantly with the EE use, increasing from 91% to 100%(p<0.001). (2) A new renal hiliar index (ReHi Index) was intro duced, with improved sensitivity and very acceptable speciÔ¨Åcity inrelation to conventional direct parameters like RePSV >200 cm/s and RAR >3.5 (p <0.0001). (3) EE showed an excellent security proÔ¨Åle in terms of renal tolerance, also allowing its use in patientswith deterioration of the renal function. 3 CARDIAC FUNCTION BY STRAIN IMAGING: KEY TO THE IN CREASED PERFORMANCE CAPACITIES OF ENDURANCE TRAINED ATHLETES P . Claessens, C. Claessens, M. Claessens, M. Claessens, J. Claessens. Eeuwfeestkliniek Antwerp Belgium. Background: To increase the performance capacity of a triath lete (Tri), a variety of adaptations are necessary. The heart is thecentral and the most important limiting factor. The structural heartadaptations in Tri have important repercussion on cardiac function.The left ventricular diastole shows speciÔ¨Åc characteristics that de termine performance capacity. Methods: 40 male Tri were compared with 31 active male con trols and with 112 patients with ischemic heart disease. All subjectsunderwent tissue Doppler and strain imaging. Results: The late diastolic Ô¨Ålling period in Tri has speciÔ¨Åc char acteristics. Tissue imaging demonstrated in Tri speciÔ¨Åc character istics of both the late passive diastolic Ô¨Ålling period and the earlyactive diastolic relaxation period. The signiÔ¨Åcant differences be tween the three groups concerning the strain values at the basaland the mid septum in the longitudinal axis by aortic valve closureand by mitral valve opening were extremely striking. The valuesof the end diastolic strain by the end of the a wave: negative inTri, near zero in normal controls, and marked positive in coronarypatients were fascinating (Ô¨Åg. 1). 204 ECHOCARDIOGRAPHY: A Jrnl. of CV Ultrasound & Allied Tech. Vol. 21, No. 2, 2004 Copyright of Echocardiography is the property of Wiley Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.\"}}], 'file_names': ['test.pdf', 'test.pdf', 'test.pdf']}", "timestamp": "2026-01-05T18:19:49.642543+00:00"}
{"asctime": "2026-01-05 23:19:49", "levelname": "INFO", "name": "utils.doctor_response", "message": "Extracted 3 reranked docs and 3 file names", "timestamp": "2026-01-05T18:19:49.647408+00:00"}
{"asctime": "2026-01-05 23:19:49", "levelname": "INFO", "name": "utils.doctor_response", "message": "Context formatted, length: 9911", "timestamp": "2026-01-05T18:19:49.648257+00:00"}
{"asctime": "2026-01-05 23:19:49", "levelname": "INFO", "name": "utils.doctor_response", "message": "Full message prepared, length: 9944", "timestamp": "2026-01-05T18:19:49.648905+00:00"}
{"asctime": "2026-01-05 23:19:49", "levelname": "INFO", "name": "utils.doctor_response", "message": "Creating OpenAI stream...", "timestamp": "2026-01-05T18:19:49.649557+00:00"}
{"asctime": "2026-01-05 23:19:57", "levelname": "INFO", "name": "httpx", "message": "HTTP Request: POST https://api.openai.com/v1/chat/completions \"HTTP/1.1 200 OK\"", "timestamp": "2026-01-05T18:19:57.921193+00:00"}
{"asctime": "2026-01-05 23:19:57", "levelname": "INFO", "name": "utils.doctor_response", "message": "OpenAI stream created successfully", "timestamp": "2026-01-05T18:19:57.923259+00:00"}
{"asctime": "2026-01-05 23:20:00", "levelname": "INFO", "name": "utils.doctor_response", "message": "Starting to stream response...", "timestamp": "2026-01-05T18:20:00.434995+00:00"}
{"asctime": "2026-01-05 23:20:00", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/chat/doctor/stream", "method": "POST", "status_code": 200, "process_time": "61467.70ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T18:20:00.441058+00:00"}
{"asctime": "2026-01-05 23:20:00", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:58602 - \"POST /api/chat/doctor/stream HTTP/1.1\" 200", "timestamp": "2026-01-05T18:20:00.441851+00:00"}
{"asctime": "2026-01-05 23:20:28", "levelname": "INFO", "name": "utils.doctor_response", "message": "Streaming completed", "timestamp": "2026-01-05T18:20:28.576605+00:00"}
{"asctime": "2026-01-05 23:36:02", "levelname": "ERROR", "name": "root", "message": "Error checking token blacklist: (psycopg2.OperationalError) server closed the connection unexpectedly\n\tThis probably means the server terminated abnormally\n\tbefore or while processing the request.\nserver closed the connection unexpectedly\n\tThis probably means the server terminated abnormally\n\tbefore or while processing the request.\n\n[SQL: SELECT login_attempts.id AS login_attempts_id, login_attempts.email AS login_attempts_email, login_attempts.attempt_time AS login_attempts_attempt_time, login_attempts.success AS login_attempts_success, login_attempts.ip_address AS login_attempts_ip_address, login_attempts.user_agent AS login_attempts_user_agent, login_attempts.failure_reason AS login_attempts_failure_reason \nFROM login_attempts \nWHERE login_attempts.failure_reason LIKE %(failure_reason_1)s AND login_attempts.success = false AND login_attempts.ip_address = %(ip_address_1)s \n LIMIT %(param_1)s]\n[parameters: {'failure_reason_1': 'blacklisted:%:16e3cb304f4fb71abc915c111c312c7ed7e9af621e169eb55ac8caf6da398854', 'ip_address_1': 'blacklist_system', 'param_1': 1}]\n(Background on this error at: https://sqlalche.me/e/20/e3q8)", "timestamp": "2026-01-05T18:36:02.245172+00:00"}
{"asctime": "2026-01-05 23:36:08", "levelname": "INFO", "name": "root", "message": "Token validated successfully for user: test@gmail.com", "timestamp": "2026-01-05T18:36:08.460957+00:00"}
{"asctime": "2026-01-05 23:36:10", "levelname": "INFO", "name": "root", "message": "Token blacklisted successfully for user test@gmail.com. Reason: logout", "timestamp": "2026-01-05T18:36:10.042436+00:00"}
{"asctime": "2026-01-05 23:36:19", "levelname": "INFO", "name": "root", "message": "Revoked 3 refresh tokens for user ID 8", "timestamp": "2026-01-05T18:36:19.353350+00:00"}
{"asctime": "2026-01-05 23:36:25", "levelname": "INFO", "name": "root", "message": "User test@gmail.com logged out successfully - 3 refresh tokens revoked", "timestamp": "2026-01-05T18:36:25.333839+00:00"}
{"asctime": "2026-01-05 23:36:26", "levelname": "INFO", "name": "root", "message": "Request completed", "path": "/api/auth/logout", "method": "POST", "status_code": 200, "process_time": "25052.52ms", "client_ip": "127.0.0.1", "timestamp": "2026-01-05T18:36:26.129756+00:00"}
{"asctime": "2026-01-05 23:36:26", "levelname": "INFO", "name": "uvicorn.access", "message": "127.0.0.1:65064 - \"POST /api/auth/logout HTTP/1.1\" 200", "timestamp": "2026-01-05T18:36:26.130860+00:00"}
